Anti-Bcl9L Antibody

Product Name

Anti-Bcl9L Antibody

View all BCL9L Antibodies

SKU/Catalog Number

A05905-1

Size

0.1 mg

Form

Liquid

Description

Boster Bio Anti-Bcl9L Antibody (Catalog # A05905-1). Tested in ELISA, WB, IHC-P, ICC, IF applications. This antibody reacts with Human.

Storage & Handling

Antibody can be stored at 4°C up to one year. Antibodies should not be exposed to prolonged high temperatures.

Cite This Product

Anti-Bcl9L Antibody (Boster Biological Technology, Pleasanton CA, USA, Catalog # A05905-1)

Host

Rabbit

Contents

Bcl9L Antibody is supplied in PBS containing 0.02% sodium azide.

Clonality

Polyclonal

Isotype

IgG

Immunogen

Bcl9L antibody was raised against a 20 amino acid synthetic peptide near the amino terminus of human Bcl9L. The immunogen is located within amino acids 20 - 70 of Bcl9L.

Cross-reactivity

Bcl9L antibody is predicted to not cross-react with other Bcl family members. At least four isoforms of Bcl9L are known to exist; this antibody will detect all four.

Reactive Species

A05905-1 is reactive to BCL9L in Human

Observed Molecular Weight

68 kDa

Calculated molecular weight

157.1 kDa

Background of BCL9L

Bcl9L, a homolog of Bcl9, was initially identified through a bioinformatics screening. It is expressed in fetal brain, adult lung, eye and prostate, in addition to several types of tumors including pancreatic and prostate cancers. Bcl9L has been shown to interact with beta-catenin, a target of the Wnt signaling pathway, and is required for enhanced beta-catenin-T-cell factor (TCF)-mediated transcription in colorectal tumor cells, possibly by translocating beta-catenin to the nucleus. Other studies have indicated that Bcl9L expression correlates with high nuclear grade cancer phenotype and the expression of ErbB2/HER-2 in breast cancers, suggesting that activity may occur in other types of cancer. Bcl9L has also been shown to be critical for Wnt-mediate regulation of stem cell traits in colon epithelium and adenocarcinomas which are associated with tumor invasion, metastasis, and resistance to therapy.

Antibody Validation

Boster validates all antibodies on WB, IHC, ICC, Immunofluorescence, and ELISA with known positive control and negative samples to ensure specificity and high affinity, including thorough antibody incubations.

View more details

Applications

A05905-1 is guaranteed for ELISA, IF, IHC-P, ICC, WB Boster Guarantee

Assay Dilutions Recommendation

The recommendations below provide a starting point for assay optimization. The actual working concentration varies and should be decided by the user.

Bcl9L antibody can be used for detection of Bcl9L by Western blot at 1 μg/mL. Antibody can also be used for immunohistochemistry starting at 5 μg/mL and immunocytochemistry starting at 10 μg/mL. For immunofluorescence start at 20 μg/mL.
Antibody validated: Western Blot in human samples; Immunohistochemistry in human samples; Immunocytochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested. Optimal dilutions for each application should be determined by the researcher.

Validation Images & Assay Conditions

See full target information BCL9L

Here are featured tools and databases that you might find useful.

• Boster's Pathways Library
• Protein Databases
• Bioscience Research Protocol Resources
• Data Processing & Analysis Software
• Photo Editing Software
• Scientific Literature Resources
• Research Paper Management Tools
• Molecular Biology Software
• Primer Design Tools
• Bioinformatics Tools
• Phylogenetic Tree Analysis